Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Morikawa S, Sakiyama T, Hasegawa H, Saijo M, Maeda A, Kurane I, Maeno G, Kimura J, Hirama C, Yoshida T, Asahi-Ozaki Y, Sata T, Kurata T, Kojima A.

J Virol. 2005 Sep;79(18):11873-91.

2.

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Kidokoro M, Tashiro M, Shida H.

Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7. Epub 2005 Mar 7.

3.

Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.

Yokote H, Shinmura Y, Kanehara T, Maruno S, Kuranaga M, Matsui H, Hashizume S.

Vaccine. 2015 Nov 9;33(45):6112-9. doi: 10.1016/j.vaccine.2015.07.076. Epub 2015 Aug 1.

4.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

5.

Serological responses in humans to the smallpox vaccine LC16m8.

Johnson BF, Kanatani Y, Fujii T, Saito T, Yokote H, Smith GL.

J Gen Virol. 2011 Oct;92(Pt 10):2405-10. doi: 10.1099/vir.0.034207-0. Epub 2011 Jun 29.

6.

Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.

Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S.

Virology. 2008 Feb 5;371(1):98-107. Epub 2007 Oct 24.

7.
8.

Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Dimier J, Ferrier-Rembert A, Pradeau-Aubreton K, Hebben M, Spehner D, Favier AL, Gratier D, Garin D, Crance JM, Drillien R.

J Virol. 2011 May;85(10):5016-26. doi: 10.1128/JVI.02359-10. Epub 2011 Mar 2.

9.

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.

J Virol. 2008 Jul;82(14):6829-37. doi: 10.1128/JVI.00353-08. Epub 2008 Apr 30.

10.

Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine.

Golden JW, Hooper JW.

Virology. 2008 Jul 20;377(1):19-29. doi: 10.1016/j.virol.2008.04.003. Epub 2008 May 14.

11.

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN.

J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.

14.
15.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

16.

Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.

17.
18.

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW.

Vaccine. 2006 Apr 24;24(17):3686-94.

PMID:
16430997
19.

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.

Coulibaly S, Brühl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG.

Virology. 2005 Oct 10;341(1):91-101.

20.

Supplemental Content

Support Center